![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Organicell Regenerative Medicine Inc (QB) | USOTC:OCELD | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.05 | 0.75 | 1.24 | 0.00 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
||
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class | Trading Symbol | Name of each exchange on which registered | ||
None | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.
Item 3.02 | Unregistered Sales of Equity Securities. |
The disclosure set forth in Item 8.01 of this Report is incorporated into this item by reference.
Item 8.01 | Other Events. |
On July 8, 2024, we completed a $500,000 private financing (the “Financing”) with a single accredited investor (the “Investor”).
In the Financing, we sold and issued to the Investor 250,000 shares of our common stock (“Shares”) and warrants to purchase an additional 83,333 Shares (the “Warrants”) for a purchase price of $500,000. Each Warrant entitles the Investor to purchase an additional Share at an exercise price of $2.00 per Share (the “Exercise Price”) for a period of ten years from the date of issuance. The Warrants are exercisable on a “cashless” basis. The Exercise Price and number of Shares issuable upon exercise of the Warrants are subject to adjustment to give effect to stock splits, stock dividends and other recapitalization events and the sale of Shares at a purchase price less than the Exercise Price then in effect. We accorded the Investor certain piggy-back registration rights under the Securities Act of 1933, as amended (the “Securities Act”) with respect to the Shares purchased and the Shares underlying the Warrants purchased.
The above securities were issued and sold pursuant to the exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder.
In addition to the foregoing, we also entered into a supply agreement with an affiliate of the Investor to sell our products to such party and entered into a non-binding term sheet with another affiliate of the Investor pursuant to which such affiliate will have the option (subject to various conditions including the negotiation and execution of definitive agreements) to invest in a newly formed subsidiary through which ZEO intends to conduct clinical trials on its present and planned products.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 12, 2024 | ZEO SCIENTIFIX, INC. | |
By: | /s/ Ian T. Bothwell | |
Ian T. Bothwell, Interim Chief Executive Officer and Chief Financial Officer |
2
Cover |
Jul. 08, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jul. 08, 2024 |
Entity File Number | 000-55008 |
Entity Registrant Name | ZEO SCIENTIFIX, INC. |
Entity Central Index Key | 0001557376 |
Entity Tax Identification Number | 47-4180540 |
Entity Incorporation, State or Country Code | NV |
Entity Address, Address Line One | 3321 College Avenue |
Entity Address, Address Line Two | Suite 246 |
Entity Address, City or Town | Davie |
Entity Address, State or Province | FL |
Entity Address, Postal Zip Code | 33314 |
City Area Code | (888) |
Local Phone Number | 963-7881 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | false |
1 Year Organicell Regenerative ... (QB) Chart |
1 Month Organicell Regenerative ... (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions